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Letters to the Editoralthough it is used differently) but re-
quires the single ventricle to pump sig-
nificantly more volume to maintain the
same cardiac output, thus decreasing
net cardiac output. The theoretic gains
in pulsatility and pulmonary vascular
resistance must be balanced by the
risks of low cardiac output, ventricu-
lotomy, and thrombosis related to the
valves in the pulmonary circuit. Nev-
ertheless, these are just theoretic pre-
dictions, and detailed in vitro and in
vivo studies are necessary to assess
the true efficacy of this and other novel
solutions. Venous and mechanical
supports that provide an additional en-
ergy source are being studied through
progressing animal models and may
offer the best hope for some patients.5
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ANTIBODY
ANTI-CYTOKERATIN CAM 5.2
IS SPECIFIC FOR
INTRACELLULAR
CYTOKERATIN 8, NOT
CYTOKERATIN 18
To the Editor:
We read with great interest the con-
tribution by Grotenhuis and colleagues
regarding the article entitled ‘‘The sen-
tinel node concept in adenocarcinomas
of the distal esophagus and gastro-
esophageal junction.’’1 However, the
authors might have inadvertently an-
notated the NCL 5D3 clone to be the
source of the murine monoclonal anti-
body CAM 5.2 and unsuitably sug-
gested CAM 5.2 to be specific to
cytokeratins 8 and 18 in their experi-
ment as well.1
We would like to comment and clar-
ify that anti-cytokeratin CAM 5.2 was
different from cytokeratin 8/18 mono-
clonal antibody. Monoclonal antibody
to cytokeratin 8/18, instead of anti-cyto-
keratin CAM 5.2, was originally devel-
oped and manufactured by Novocastra
Laboratories Ltd (Newcastle Upton
Tyne,UnitedKingdom)using the brand
Novocastra. The company grew and in
2003 was integrated into Vision Bio-
Systems (Wetzlar, Germany). Today,
Novocastra has become an important
part of the overall histology range ofLe-
icaMicrosystems’BiosystemsDivision
through this definitive merger.
Therefore, monoclonal antibody to
cytokeratin 8/18 is produced by Leica
Microsystems’ Biosystems Division,
which is derived from the 5D3 clone.Cardiovascular Surgery c June 2010This clone reacts with human
cytokeratin-intermediate filament pro-
teins at 52.5 and 45 kd, which are
identified as cytokeratins 8 and 18,
respectively.2 On the other hand,
anti-cytokeratin CAM 5.2 reagent is
produced by Becton Dickinson Biosci-
ences (Franklin Lakes, NJ) and is de-
rived from the clone CAM 5.2. This
clone reacts with human cytokeratin-
intermediate filament proteins at 48
and 52 kd, which are identified as cyto-
keratins 7 and 8, respectively.3 In addi-
tion, Becton Dickinson Biosciences
(1977) revised the data sheet for anti-
cytokeratin CAM5.2 to have a primary
reactivity with cytokeratin 8 and, in
addition, a weaker but distinct reactiv-
ity with cytokeratin 7. The data sheet
also shows that there is no reactivity
with cytokeratins 18 or 19. As a result,
CAM 5.2 is not synonymous with
cytokeratins 8 and 18.4 We concluded
that the murine monoclonal antibody
CAM 5.2 will not be specific for
intracellular cytokeratins 8 and 18.
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We thank our colleagues Cheng and
associates for their commentary with
regard to our recently published article,
‘‘The Sentinel Node Concept in Ade-
nocarcinomas of the Distal Esophagus
and Gastroesophageal Junction.’’1 In
this study, we used the widely recog-
nized immunohistochemical assay in
which antibodies against epithelial-
cell proteins are used to detect small
clusters of tumor cells in histologically
node-negative lymph nodes of patients
with esophageal adenocarcinoma. Yao
and Han claim that the monoclonal an-
tibody against cytokeratin 8 and 18
(clone NCL-5D3) that we used in the
present study should not be mistaken
with the CAM5.2 antibody (clone
CAM5.2) that appears to be specific
for cytokeratin 7 and 8. In our article,
we stated that the used antibody
CAM 5.2 is specific for intracellular
cytokeratin 8 and 18, referring to the
original paper of Makin, Bobrow, and
Bodmer,2 in which it is claimed that
(at that time newly developed)
antibody CAM5.2 identifies the lower
molecular weight cytokeratins (cyto-
keratin 8, 18 and 19). Other studies
that investigated the presence and
relevance of micrometastases or iso-
lated tumor cells by using antibody
CAM5.2 have also referred to this arti-
cle.3 However, over the last years,
companies producing these antibodiesThe Journalhave changed their products and fur-
ther investigated the corresponding
specificity in reactivity against certain
cytokeratins, as pointed out by Yao
and Han. Therefore, their statement
that antibody CAM5.2 is not specific
for intracellular cytokeratin 8 and 18
is correct. Nevertheless, this finding
does not affect the conclusions of our
study. The presence of cytokeratin 8
and/or 18 (which are both expressed
in esophageal adenocarcinoma4) as
detected with the antibody used in
our study (clone NCL-5D3) indicates
epithelial cell deposits in lymphoid
tissue. Therefore, these cytokeratin
deposits will still imply the presence
of micrometastatic disease.
Brechtje A. Grotenhuis
Bas P. L. Wijnhoven
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SURGICAL OR
ENDOVASCULAR
ENHANCEMENT OF
NONCORONARY COLLATERAL
CIRCULATION: A NEW
RESEARCH FIELD
To the Editor:
We read with great interest the arti-
cle by Atluri and colleagues,1 and weof Thoracic and Cardiovascular Surgercongratulate them for their experi-
ments with myocardial perfusion and
contractility improvement using a laser
transmyocardial approach. We agree
with the authors that the problem
with myocardial revascularization in
patients who might not benefit from
conventional procedures still demands
investigative efforts. This was the gen-
esis of a research program we began at
Laval University in Quebec and that
we are going to start in Europe at Uni-
versite´ Paris Sud. This program is
aimed at the enhancement of noncoro-
nary collateral circulation (NCCC).
Our animal models are dogs (Canada)
and pigs (France).
NCCC is a topic that is virtually ig-
nored,with very fewpublications in ex-
istence. This is surprising, considering
that it is not rare to find evidence of
NCCC, such as during coronary bypass
surgerywhen arterial blood flowcomes
from the coronary ostia during valve re-
placement surgery or from the incised
coronary artery, despite adequate aortic
crossclamping and venting. NCCC
consists of a network of small channels
that come from mediastinal, bronchial,
and pericardial vessels and that enter
the heart through the pericardial reflec-
tions surrounding the pulmonary and
systemic veins, as well as through the
vasa vasorum of the aorta and pulmo-
nary artery leading to and from the
myocardium. Our studies are premised
on the belief that this network is bigger
than generally thought and that it might
play a role, if adequately enhanced, as
an alternative means of myocardial
blood supply. We also believe that the
normal ventricular function sometimes
seen in patients with occlusion of the 3
major coronary vessels can be evidence
of myocardial nourishment related to
such a collateral source. Previous stud-
ies2 have shown that vascular connec-
tions exist between the internal
thoracic arteries (ITAs) and myocar-
dium and that surgical bilateral ligation
of the ITAs creates a local hypertensive
status, increasing the perfusion pres-
sure within the channels leading to the
heart.3y c Volume 139, Number 6 1675
